Humana Inc. (HUM), headquartered in Louisville, Kentucky, provides medical and specialty insurance products. With a market cap of $46.7 billion, the company offers coordinated health care through health maintenance organizations, point-of-service plans, and administrative services products.
Shares of medicare giant have outperformed the broader market over the past year. HUM has gained 36.5% over this time frame, while the broader S&P 500 Index ($SPX) has rallied nearly 20.6%. In 2026, HUM stock is up 50.3%, surpassing the SPX’s 13.9% rise on a YTD basis.
More Top Stocks Daily: Go behind Wall Street’s hottest headlines with Barchart’s Active Investor newsletter.
Zooming in further, HUM’s outperformance is also apparent compared to the iShares U.S. Healthcare Providers ETF (IHF). The exchange-traded fund has gained about 29.1% over the past year. Moreover, HUM’s returns on a YTD basis outshine the ETF’s 18.7% gains over the same time frame.
www.barchart.com Humana beat estimates thanks to stronger operational efficiency and improvements in its Stars ratings. Cost trends remained favorable, particularly among value-based care members, while G&A savings from centralizing functions and expanding outsourcing provided additional margin support. Management also reaffirmed its 2028 margin target and outlined plans for 2027 Medicare Advantage plan exits to focus on higher-value products. In addition, the company is using proceeds from the Gentiva sale to fund the MaxHealth acquisition, and a new Illinois Medicaid contract is helping drive growth beyond its core Medicare Advantage business.
On Jul. 29, HUM shares closed down by 6% after reporting its Q2 results. Its adjusted EPS of $7.61 exceeded Wall Street expectations of $6.22. The company’s adjusted revenue was $40.9 billion, topping Wall Street forecasts of $40.7 billion. HUM expects full-year adjusted EPS to be $9.
For the current fiscal year, ending in December, analysts expect HUM’s EPS to decline 47% to $9.09 on a diluted basis. The company’s earnings surprise history is impressive. It beat the consensus estimate in each of the last four quarters.
Among the 26 analysts covering HUM stock, the consensus is a “Moderate Buy.” That’s based on 12 “Strong Buy” ratings, 13 “Holds,” and one “Strong Sell.”
www.barchart.com This configuration is more bullish than a month ago, with nine analysts suggesting a “Strong Buy,” one advising a “Moderate Buy,” and two recommending a “Strong Sell.”
On Aug. 10, JPMorgan Chase & Co. (JPM) analyst Lisa Gill kept a “Neutral” rating on HUM and raised the price target to $393, implying a potential upside of 2.1% from current levels.
The mean price target of $419.61 represents a 9% premium to HUM’s current price levels. The Street-high price target of $513 suggests a notable upside potential of 33.3%.
On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
More news from Barchart
S&P Futures Tick Higher With Focus on U.S. Retail Sales Data H&R Block Posted Strong Earnings and Boosted Its Dividend by Nearly 10%. What This Means for HRB Stock. CEO Steve Huffman Once Said of Creating Reddit, ‘I Just Didn't Want To Look Stupid In Front Of My Parents’ — Now RDDT Stock is Joining the S&P 500 Index Ahead of Sidus Space Earnings, Here's What Barchart Data Says Comes Next for SIDU Stock